title: [Hyperprolactinemia: importance of early therapy].
authors.forename: H
authors.initials: H
authors.lastname: Rachidi-Koussa
authors.forename: N
authors.initials: N
authors.lastname: Vergely
authors.forename: R
authors.initials: R
authors.lastname: Duthel
authors.forename: J
authors.initials: J
authors.lastname: Malluret
authors.forename: B
authors.initials: B
authors.lastname: Estour
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000378:metabolism; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000150:complications*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy / Q000209:etiology*; D009364:Neoplasm Recurrence, Local; D010911:Pituitary Neoplasms / Q000150:complications* / Q000378:metabolism; D013997:Time Factors; D001615:beta-Endorphin / Q000378:metabolism*
chemical_list: D001971:Bromocriptine; D001615:beta-Endorphin
vernacular_title: Hyperprolactinémie: attention aux thérapeutiques hâtives.